News Articles and Montana BioScience Alliance Newsletters
Inimmune Corp., a leader in developing the next generation of vaccines and immunotherapeutics, announced today that Dr. Alan Joslyn has been appointed President and Chief Executive Officer of the company. Dr. Joslyn will also join the Inimmune Board of Directors as CEO.
How did the United States, a global superpower, get caught so flatfooted when the COVID-19 pandemic hit? A big reason was sleeping through the decline of domestic pharmaceutical manufacturing, allowing most development and manufacturing capabilities and jobs to leave the U.S. for foreign countries.
The University of Montana in Missoula and Montana State University in Bozeman have achieved “R1” designations for their research programs. The “R1” classification is conferred by the Carnegie Classification of Institutions of Higher Education organization based on factors including research expenditures, staffing, and number of doctorates awarded.
Montana State University Billings announces the launch of the Institute for Neurodiversity and Applied Behavior Analysis at the Montana Center for Inclusive Education (MCIE) on university campus. The Institute will serve children in the region with mental, social, and behavioral differences associated with autism spectrum disorders, developmental disabilities, similar mental health disorders, and other behavioral disabilities, by providing direct and telehealth clinical support.
BioScience Laboratories, a Nelson Labs company located in Bozeman, MT, and a leader in topical antimicrobial-product testing in the consumer, pharmaceutical, and medical-device industries, operates a biosafety-level-3 (BSL-3) laboratory that was inspected by the Centers for Disease Control and Prevention (CDC) last year. The CDC has since confirmed that the Bozeman facility’s BSL-3 lab and related procedures adequately meet guidelines for the company to test all common and concerning strains of SARS-CoV-2 and other potentially dangerous pathogens.
Researchers from Diaceutics and the Personalized Medicine Coalition has published a special report in JCO Precision Oncology that provides an in-depth look at United States health systems’ efforts to deploy potentially paradigm-shifting targeted and immuno-oncology drugs to improve care for lung cancer patients.
Doctors have told health services to prepare for a new era of cancer screening after a study found a simple blood test could spot multiple cancer types in patients before they develop clear symptoms.
It’s been 60 years since President Kennedy delivered his iconic moonshot speech, marking a goal for America to launch a man into space to step foot on the moon, and bring him back to Earth. On Sept. 12, President Biden gave a speech at the Kennedy Presidential Library in Boston, outlining the progress on his own self-described moonshot: ending cancer.
The National Institute on Aging (NIA) offers early-stage funding opportunities to small businesses and researchers looking to commercialize innovative treatments or technologies to help people enjoy healthier lives as they age. The NIA Small Business Program is accepting applications for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding. Learn more about these open opportunities. The next deadline to apply is September 6, 2022.
The federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs offer a lifeline to small medical technology companies that otherwise would not be able to secure the initial funding necessary for expensive research and development.